ReviewAmerican journal of translational research2015
Introduction to next generation of endothelial progenitor cell therapy: a promise in vascular medicine.
Review in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 68 citations in OpenAlex.
- Endothelial Cells Offer a Better Option than Smooth Muscle Cells for the Treatment of Ischemic Limb Disease.Cells · 2026Article
- Isolation of endothelial progenitor cells from human adipose tissue.International journal of obesity (2005) · 2025Article
- Anti-inflammatory Prowess of endothelial progenitor cells in the realm of biology and medicine.NPJ Regenerative medicine · 2024Review
- Novel cell therapy withRegenerative therapy · 2024Article
- Berberine ameliorates endothelial progenitor cell function and wound healingRegenerative therapy · 2024Article
- Review
- The Role of Angiogenesis and Arteriogenesis in Myocardial Infarction and Coronary Revascularization.Journal of cardiovascular translational research · 2022Review
- Constructing a heparin-modified penile decellularized scaffold to improve re-endothelialization in organizational reconstruction.Translational andrology and urology · 2022Article
- Old and new therapeutic strategies in systemic sclerosis (Review).Experimental and therapeutic medicine · 2022Review
- Recent Advances on Cell-Based Co-Culture Strategies for Prevascularization in Tissue Engineering.Frontiers in bioengineering and biotechnology · 2021Review
- Review
- Atherosclerotic Pre-Conditioning Affects the Paracrine Role of Circulating Angiogenic Cells Ex-Vivo.International journal of molecular sciences · 2020Article
- Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia.Stem cell research & therapy · 2020Article
- MicroRNA-126 protects against vascular injury by promoting homing and maintaining stemness of late outgrowth endothelial progenitor cells.Stem cell research & therapy · 2020Article
- Iron (III)-Quercetin Complex: Synthesis, Physicochemical Characterization, and MRI Cell Tracking toward Potential Applications in Regenerative Medicine.Contrast media & molecular imaging · 2020Article
- Towards clinical application of tissue engineering for erectile penile regeneration.Nature reviews. Urology · 2019Review
- Article
- Bone marrow derived endothelial progenitor cells retain their phenotype and functions after a limited number of culture passages and cryopreservation.Cytotechnology · 2019Article
- Improving the Angiogenic Potential of EPCs via Engineering with Synthetic Modified mRNAs.Molecular therapy. Nucleic acids · 2018Article
- Effectiveness of endothelial progenitor cell culture under microgravity for improved angiogenic potential.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concept of Endothelial Progenitor Cells (EPCs) therapy for adult neovascularization has continuously received attention. They are believed to participate in endothelial repair and post natal angiogenesis due to their abilities in differentiating into endothelial cells and producing protective cytokines and growth factors. Abundant evidence supports the involvement of EPCs in capillary growth and in participating in the formation of collateral vessels, which lead to improved vascular perfusion and functional recovery in target tissue. Autologous EPC now is becoming a novel treatment option for therapeutic revascularization and vascular repair in ischemic diseases. However, various diseases such as diabetes, heart disease and ischemic diseases are related to EPC dysfunction and give rise to additional challenges of autologous EPC therapy. A novel strategy to enhance the number and function of EPCs is needed to be established to provide successful autologous EPCs therapy. Currently, clinical trials for the new generation of EPC therapy in treating peripheral ischemic diseases are underway. In this review we provide an overview and the limitations of current EPCs therapy with an introduction to the new strategies of next generation EPC therapy for more promising vascular and tissue regeneration therapy.
Indexed as
Identifiers
26045883PMC4448183W2414800928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.